Table 4.
Ketamine‐like drugs
| Target Mechanism | Compound | Clinical Trial Phase | Sponsor |
|---|---|---|---|
|
NMDR (nonselective) |
AXS‐05 | III | Axsome Therapeuitics |
|
NMDAR Antagonist (nonselective) |
AVP‐786 | II | Avanir/Otsuka |
|
NMDAR Antagonist (nonselective) |
Esketamine (intranasal) |
III | JNJ/Janssen |
| NR2B Subunit | CERC‐301 | II | Cerecor |
|
NR2B Subunit (Modulator with GlyB site (partial agonist) |
GLYX‐13/NRX‐1074 Rapastinel (IV) |
III | Allergan |
| NR2B Subunit | AV‐101 | II | VistaGen |
NMDAR, N‐methyl‐D‐aspartate receptor, NR2B, N‐methyl D‐aspartate receptor subtype B.